Search results
Results from the WOW.Com Content Network
Cipla also cooperates with other enterprises in areas such as consulting, commissioning, engineering, project appraisal, quality control, know-how transfer, support, and plant supply. During the FY 2013–14, the company incurred ₹ 1,285 crore (equivalent to ₹ 21 billion or US$240 million in 2023) on employee benefit expenses.
Cadila was founded in 1952 by Ramanbhai Patel (1925–2001), formerly a lecturer in the L.M. College of Pharmacy, and his business partner Indravadan Modi. [8]In 1995, the Patel and Modi families split; the Modi family's share was moved into a new company called Cadila Pharmaceuticals, and Cadila Healthcare became the Patel family's holding company.
Sun Pharmaceutical Industries Ltd. was established by Dilip Shanghvi in 1983 in Calcutta, West Bengal with five psychiatry products and a two-person marketing team. Today it is ranked number one in share of prescriptions with 12 classes of doctors in India and a market leader in Psychiatry, Neurology, Cardiology, Orthopaedics, Gastroenterology, Nephrology, Diabetology, Dermatology, Urology ...
Cipla, India's No.3 generic drugmaker by sales, reported a better-than-expected quarterly profit on Friday, boosted by strength in its key domestic and North American businesses. The results come ...
HYDERABAD/BENGALURU (Reuters) -Cipla, India's third-largest generics drugmaker by sales, beat first-quarter profit estimates on Friday as it reported higher sales in its North America market ...
In 2003, the Directorate of Science and Technology, Government of India approved the facilities as a commercial Research and Development (R&D) company. In 2006-07 Rubicon licensed its Orodispersible excipient, RubiODT to Mallinckrodt Baker, Inc. [2] In 2009 the company commission an oral solids manufacturing plant in Ambernath, India.
BENGALURU (Reuters) -Indian drugmaker Cipla said on Friday its U.S. unit was recalling six batches of albuterol sulfate inhalation aerosol due to a "container defect". "The company is initiating a ...
Thakur left India for the United States and contacted the Food and Drug Administration (FDA), which started investigating his claims. [17] As a result, on 16 September 2008, the Food and Drug Administration issued two warning letters to Ranbaxy Laboratories Ltd. and an Import Alert for generic drugs produced by two manufacturing plants in India ...